{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T08:27:25Z","timestamp":1759480045648},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,7,9]],"date-time":"2020-07-09T00:00:00Z","timestamp":1594252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Whether C5 blocking may improve the outcomes of patients developing chemotherapy-induced thrombotic microangiopathy (TMA) remains elusive. Lung fibrosis is a well-known complication of bleomycin, whereas TMAs are very rare (&amp;lt;20 cases described). Here, we report an exceptional case of a male patient that developed acute respiratory distress syndrome and TMA following administration of bleomycin, cisplatin and etoposide . Refractoriness to plasma exchanges prompted us to use eculizumab as salvage therapy. Eculizumab led to complete remission of the TMA before Day 2. However, the patient progressed towards refractory respiratory failure, suggesting that pathophysiological mechanisms of bleomycin-induced lung fibrosis and TMA differ.<\/jats:p>","DOI":"10.1093\/ckj\/sfaa101","type":"journal-article","created":{"date-parts":[[2020,5,28]],"date-time":"2020-05-28T19:12:39Z","timestamp":1590693159000},"page":"1275-1276","source":"Crossref","is-referenced-by-count":8,"title":["Complement C5 inhibition reverses bleomycin-induced thrombotic microangiopathy"],"prefix":"10.1093","volume":"14","author":[{"given":"Sofiane","family":"Salhi","sequence":"first","affiliation":[{"name":"Department of Nephrology and Organ Transplantation, Centre for Rare Renal Diseases, University Hospital of Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ribes","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Organ Transplantation, Centre for Rare Renal Diseases, University Hospital of Toulouse, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stanislas","family":"Faguer","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Organ Transplantation, Centre for Rare Renal Diseases, University Hospital of Toulouse, Toulouse, France"},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, U1048\u2013Institut des Maladies M\u00e9taboliques et Cardiovasculaires, French Intensive care Renal Network, Toulouse, France"},{"name":"Universit\u00e9 Paul Sabatier, Toulouse 3, Toulouse, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,7,9]]},"reference":[{"key":"2021060310400920800_sfaa101-B1","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","article-title":"Haemolytic uraemic syndrome","volume":"390","author":"Fakhouri","year":"2017","journal-title":"Lancet"},{"key":"2021060310400920800_sfaa101-B2","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ckj\/sft078","article-title":"Eculizumab and drug-induced haemolytic-uraemic syndrome","volume":"6","author":"Faguer","year":"2013","journal-title":"Clin Kidney J"},{"key":"2021060310400920800_sfaa101-B3","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bcp.13808","article-title":"Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort","volume":"85","author":"Daviet","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"2021060310400920800_sfaa101-B4","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7326\/0003-4819-105-1-48","article-title":"Acute vascular ischemic events after cisplatin-based combination chemotherapy for germ-cell tumors of the testis","volume":"105","author":"Doll","year":"1986","journal-title":"Ann Intern Med"},{"key":"2021060310400920800_sfaa101-B5","doi-asserted-by":"crossref","first-page":"2336","DOI":"10.1096\/fj.201500044","article-title":"Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis","volume":"30","author":"Gu","year":"2016","journal-title":"FASEB J"}],"container-title":["Clinical Kidney Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/4\/1275\/38462614\/sfaa101.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ckj\/article-pdf\/14\/4\/1275\/38462614\/sfaa101.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T10:42:12Z","timestamp":1622716932000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ckj\/article\/14\/4\/1275\/5869073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,9]]},"references-count":5,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,7,9]]},"published-print":{"date-parts":[[2021,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/ckj\/sfaa101","relation":{},"ISSN":["2048-8513"],"issn-type":[{"value":"2048-8513","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,7,9]]}}}